Linganisha mbinu

	Utafiti wa Kesi-Udhibiti wa Vituo vingi	Jaribio la Kimatibabu Lililodhibitiwa kwa Nasibu la Vituo Vingi
Nyanja	Epidemiolojia	Epidemiolojia
Familia	Process / pipeline	Process / pipeline
Mwaka wa asili	Mid-20th century; multicenter framework formalised 1970s–1980s	1970s–1980s (widespread adoption for large-scale efficacy trials)
Mwanzilishi	Epidemiology convention; seminal statistical framework by Breslow & Day (IARC, 1980)	Evolved from single-center RCT methodology; consolidated through landmark trials such as the MRC streptomycin trial (1948) and large cardiovascular mega-trials of the 1970s–1980s
Aina	Observational analytical epidemiological design	Interventional experimental design
Chanzo asilia	Breslow, N. E., & Day, N. E. (1980). Statistical Methods in Cancer Research. Volume I: The Analysis of Case-Control Studies. IARC Scientific Publications No. 32. International Agency for Research on Cancer, Lyon. ISBN: 978-9283211327	Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015). Fundamentals of Clinical Trials (5th ed.). Springer. ISBN: 978-3319185385
Majina mbadala	multisite case-control study, collaborative case-control study, pooled case-control study, multi-institutional case-control study	multi-site RCT, multicenter RCT, multinational randomized trial, multicenter controlled trial
Zinazohusiana	6	6
Muhtasari	A multicenter case-control study is an observational design that identifies individuals who have developed a disease (cases) and disease-free comparators (controls) across two or more study sites simultaneously. By pooling recruitment across hospitals, clinics, or geographic regions, the design achieves larger sample sizes, captures exposure variability over broader populations, and improves the statistical power needed to detect modest odds ratios for rare or heterogeneous diseases.	A multicenter randomized clinical trial (RCT) is an experimental study in which eligible participants are randomly assigned to intervention or control arms simultaneously across two or more clinical sites. By combining the rigor of randomization with enrollment from geographically or institutionally diverse centers, this design produces large samples and externally valid effect estimates that single-center trials rarely achieve. It is the regulatory gold standard for confirmatory efficacy and safety evaluation of new treatments.